Loading clinical trials...
Loading clinical trials...
This is a randomized, rater blinded trial in patients who interrupt treatment with natalizumab with or without being treated with other immunomodulatory drugs, or continue treatment with natalizumab. ...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Biogen
Collaborators
NCT04047628 · Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, and more
NCT06663111 · Relapsing Remitting Multiple Sclerosis
NCT04602390 · Multiple Sclerosis (MS), Relapsing Remitting Multiple Sclerosis
NCT05978531 · Relapsing Remitting Multiple Sclerosis
NCT04225312 · Relapsing Remitting Multiple Sclerosis
Research Site
Cullman, Alabama
Research Site
San Francisco, California
Research Site
Fort Collins, Colorado
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions